Top

Molecular Imaging and Biology

Published in:

01-06-2016 | Research Article

In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57

Authors: Johan Hygum Dam, Birgitte Brinkmann Olsen, Christina Baun, Poul-Flemming Høilund-Carlsen, Helge Thisgaard

Published in: Molecular Imaging and Biology | Issue 3/2016

Abstract

Purpose

The purpose of this study was to apply an analogue of bombesin, NOTA-AMBA, labeled with Co-55 or Ga-68, for preclinical imaging of prostate cancer.

Procedures

The peptide NOTA-AMBA was labeled with Ga-68 or Co-55 by microwave irradiation. Biodistribution in xenograft mice (PC3) was performed at 1, 4, and 24 h (only cobalt at 24 h) using a fixed amount of peptide. Four weeks post-inoculation, xenograft mice were positron emission tomography/X-ray computed tomography scanned after tail vein injection of [⁶⁸Ga]NOTA-AMBA or [⁵⁵Co]NOTA-AMBA.

Results

Labeling with Ga-68 and Co-55/57 was achieved in yields greater than 90 %. A radiochemical purity (RCP) of 95 and 90 % were obtained for Ga-68 and Co-55, respectively. Both radiopeptides showed high uptake in the intestines, stomach, pancreas, and in the tumor ([⁶⁸Ga]NOTA-AMBA, 10.3 %ID/g at 1 h to 6.4 %ID/g at 4 h; [⁵⁷Co]NOTA-AMBA, 8.2 %ID/g at 1 h to 5.3%ID/g at 24 h). Normal tissue cleared over time improving tumor-to-background ratios.

Conclusions

NOTA-AMBA was labeled in high yields and RCP with Ga-68 and Co-55/57. High tumor uptake in a subcutaneous mouse prostate cancer model was observed. At 24 h, [^55/57Co]NOTA-AMBA showed better tumor-to-organ ratios than [⁶⁸Ga]NOTA-AMBA at both 1 and 4 h post-injection. Hence, for imaging, [⁵⁵Co]NOTA-AMBA was found to be superior compared to [⁶⁸Ga]NOTA-AMBA.

Ananias H, de Jong I, Dierckx R et al (2008) Nuclear imaging of prostate cancer with gastrin-releasing-peptide- receptor targeted radiopharmaceuticals. Curr Pharm Des 14:3033–3047CrossRefPubMed

Fani M, Maecke HR, Okarvi SM (2012) Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2:481–501CrossRefPubMedPubMedCentral

Fani M, Maecke HR (2012) Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 39(Suppl 1):S11–S30CrossRefPubMed

Schottelius M, Wester H-J (2009) Molecular imaging targeting peptide receptors. Methods 48:161–177CrossRefPubMed

Schroeder RPJ, van Weerden WM, Bangma C et al (2009) Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 48:200–204CrossRefPubMed

Smith CJ, Volkert WA, Hoffman TJ (2005) Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol 32:733–740CrossRefPubMed

Varasteh Z, Velikyan I, Lindeberg G et al (2013) Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging. Biocojugate Chem 24:1144–1153CrossRef

Gourni E, Mansi R, Jamous M et al (2014) N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. J Nucl Med 55:1719–1725CrossRefPubMed

Kroll C, Mansi R, Braun F et al (2013) Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. J Am Chem Soc 135:16793–16796CrossRefPubMed

10.

Mansi R, Wang X, Forrer F et al (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249CrossRefPubMed

11.

Mansi R, Wang X, Forrer F et al (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97–107CrossRefPubMed

12.

Breeman WA, Hofland LJ, de Jong M et al (1999) Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 81:658–665CrossRefPubMed

13.

Liu Y, Hu X, Liu H et al (2013) A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer. J Nucl Med 54:2132–2138CrossRefPubMedPubMedCentral

14.

Asti M, Iori M, Capponi PC et al (2014) Influence of different chelators on the radiochemical properties of a 68-gallium labelled bombesin analogue. Nucl Med Biol 41:24–35CrossRefPubMed

15.

Koumarianou E, Loktionova NS, Fellner M et al (2012) 44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET? Appl Radiat Isot 70:2669–2676CrossRefPubMed

16.

Gourni E, Del Pozzo L, Kheirallah E et al (2015) Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Mol Pharm 12:2781–2790. doi:10.1021/mp500671j CrossRefPubMed

17.

Pan D, Xu YP, Yang RH et al (2014) A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids 46:1481–1489CrossRefPubMed

18.

Schroeder RPJ, Müller C, Reneman S et al (2010) A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 37:1386–1396CrossRefPubMedPubMedCentral

19.

Heppeler A, André JP, Buschmann I et al (2008) Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry 14:3026–3034CrossRefPubMed

20.

Braad PEN, Hansen SB, Thisgaard H, Høilund-Carlsen PF (2015) PET imaging with the non-pure positron emitters: 55Co, 86Y and 124I. Phys Med Biol 60:3479–3497CrossRefPubMed

21.

Thisgaard H, Olesen ML, Dam JH (2011) Radiosynthesis of 55Co- and 58mCo-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy. J Label Compd Radiopharm 54:758–762CrossRef

22.

Thisgaard H, Olsen BB, Dam JH et al (2014) Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy. J Nucl Med 55:1311–1316CrossRefPubMed

23.

Waser B, Eltschinger V, Linder K et al (2007) Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA. Eur J Nucl Med Mol Imaging 34:95–100CrossRefPubMed

24.

Schroeder RPJ, van Weerden WM, Krenning EP et al (2011) Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 38:1257–1266CrossRefPubMedPubMedCentral

25.

Reubi JC, Wenger S, Schmuckli-maurer J et al (2002) Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] bombesin (6–14). Clin Cancer Res 8:1139–1146PubMed

26.

Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 18:1457–1466CrossRefPubMed

27.

Cagnolini A, Chen J, Ramos K et al (2010) Automated synthesis, characterization and biological evaluation of [(68)Ga]Ga-AMBA, and the synthesis and characterization of (nat)Ga-AMBA and [(67)Ga]Ga-AMBA. Appl Radiat Isot 68:2285–2292CrossRefPubMed

28.

Lantry LE, Cappelletti E, Maddalena ME et al (2006) 177Lu-AMBA: synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 47:1144–1152PubMed

29.

Liu I, Chang C-H, Ho C et al (2010) Multimodality imaging and preclinical evaluation of 177Lu-AMBA for human prostate tumours in a murine model. Anticancer Res 30:4039–4048PubMed

30.

Ho C-L, Liu I-H, Wu Y-H, et al. (2011) Molecular imaging, pharmacokinetics, and dosimetry of In-AMBA in human prostate tumor-bearing mice. J Biomed Biotechnol 1

31.

Wild D, Frischknecht M, Zhang H et al (2011) Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 71:1009–1018CrossRefPubMed

32.

De Blois E, Schroeder RPJ, de Ridder CMA, van Weerden WM, Breeman WAP, de Jong M (2013) Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-mediated imaging of prostate cancer. Q J Nucl Med Mol Imaging 57:1–9

33.

Ciatto S, Zappa M, Bonardi R, Gervasi G (2000) Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. Eur J Cancer 36:1347–1350CrossRefPubMed

Title: In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57
Authors: Johan Hygum Dam
Birgitte Brinkmann Olsen
Christina Baun
Poul-Flemming Høilund-Carlsen
Helge Thisgaard
Publication date: 01-06-2016
Publisher: Springer US
Published in: Molecular Imaging and Biology / Issue 3/2016
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-015-0911-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

In Vivo Evaluation of a Bombesin Analogue Labeled with Ga-68 and Co-55/57

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2016

[11C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice

Convenient Preparation of [68Ga]DKFZ-PSMA-11 Using a Robust Single-Vial Kit and Demonstration of Its Clinical Efficacy

Biodistribution of [68Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions

Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer

Image quality of Zr-89 PET imaging in the Siemens microPET Focus 220 preclinical scanner

A Novel Imaging Biomarker Extracted from Fluorescence Microscopic Imaging of TRA-8/DR5 Oligomers Predicts TRA-8 Therapeutic Efficacy in Breast and Pancreatic Cancer Mouse Models